bmslogo

BMS says Phase III trials for Opdivo show improved overall survival in lung cancer

pharmafile | May 19, 2016 | News story | Research and Development Bristol-Myers Squibb, drug trial, lung cancer, opdivo 

Bristol-Myers Squibb (NYSE:BMY) said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the two-year time point.

The trials were to evaluate overall survival via two pivotal Phase III studies versus docetaxel in previously treated metastatic non-small cell lung cancer (NSCLC). In addition, the safety profile of Opdivo at two years was consistent with previous reports of data from both studies.

Hossein Borghaei, chief, Thoracic Oncology, Fox Chase Cancer Center, said: “Data presented at ASCO underscore the potential of Opdivo to improve long-term outcomes for patients with this particularly challenging disease.”

Nick Botwood development lead, Lung and Head & Neck, Bristol-Myers Squibb, said: “Today, these data from CheckMate -057 and -017 expand our understanding of the potential for Opdivo to provide a meaningful, durable survival benefit to patients with previously treated metastatic NSCLC.”

Anjali Shukla

Related Content

Roche’s Alecensa approved by FDA as lung cancer treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …

FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment

Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its …

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …

Latest content